# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jacqueline du Pré (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML039-SYN
- Date: 2026-04-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Imogen Thackeray-Osei, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Second half-dose of the first ocrelizumab course. **S**

## History of present illness

Ms. du Pré comes on the day of her second 300 mg dose of ocrelizumab. The three days of intravenous methylprednisolone a month ago caused a few nights of poor sleep and a metallic taste, and within two weeks the feeling in her fingers began to come back. The first infusion two weeks ago caused an itchy throat and flushing an hour in, which settled when the rate was slowed. She has worked with the occupational therapist on finger exercises and practices in 20-minute blocks, about two hours a day, and has played through slow movements without losing her place. The electric feeling on bending her head is fainter. Her blood tests before the first infusion were normal. She is less tired. **S**

| Element | Detail |
|---|---|
| Treatment | Methylprednisolone 1 g for 3 days; ocrelizumab 300 mg two weeks ago; second 300 mg today |
| Infusion reaction | Mild throat itch and flushing with the first dose, settled by slowing the rate |
| Hand function | Feeling returning; practicing two hours a day in short blocks |
| Vaccination | Hepatitis B dose 2 today |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Less tired; no fever |
| Neurological | Positive | Tingling in the left fingertips, less than before; Lhermitte's sign fainter; no new symptoms |
| Ears, nose, mouth, and throat | Negative | Throat itch with the first infusion only |
| Genitourinary | Negative | No urinary symptoms |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Hopeful; PHQ-9 5; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily **S**
- Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 64.6 kg; BMI 21.6 kg/m². All vital signs are synthetic.

Hemoglobin: 13.6 g/dL; White cell count: 7.9 10*3/uL; Lymphocytes: 1.6 10*3/uL; Platelets: 252 10*3/uL; Glucose: 90 mg/dL; ALT: 21 U/L; AST: 22 U/L; PHQ-9: 5; Nine-hole peg test, right hand: 20.5 s; Nine-hole peg test, left hand: 23 s. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.4 g/dL at baseline, 13.6 g/dL at this visit **S**
- White cell count: 6.4 10*3/uL at baseline, 7.9 10*3/uL at this visit **S**
- Lymphocytes: 1.9 10*3/uL at baseline, 1.6 10*3/uL at this visit **S**
- Platelets: 246 10*3/uL at baseline, 252 10*3/uL at this visit **S**
- Glucose: 86 mg/dL at baseline, 90 mg/dL at this visit **S**
- ALT: 16 U/L at baseline, 21 U/L at this visit **S**
- AST: 19 U/L at baseline, 22 U/L at this visit **S**
- Nine-hole peg test, right hand: 26 s at baseline, 20.5 s at this visit **S**
- Nine-hole peg test, left hand: 33.5 s at baseline, 23 s at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (adjuvanted, two-dose series), dose 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 64.6 kg, up 1.2 kg after steroids; blood pressure 118/74 |
| Neurological | Vibration and joint position sense now only slightly reduced in the left fingers; no wandering of the fingers; strength normal; Lhermitte's sign faint. Nine-hole peg test 20.5 seconds right, 23.0 seconds left |
| Skin | No rash |
| Psychiatric | Brighter and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Relapsing-remitting multiple sclerosis, on ocrelizumab** (G35.A). Good recovery from the relapse after steroids and occupational therapy: nine-hole peg times down from 24.5 and 31.0 to 20.5 and 23.0 seconds. The first infusion caused a mild infusion reaction, which is common with the first dose. Blood count and liver tests are normal and the glucose is normal after steroids. Urine pregnancy test negative today. **S**
   - Ocrelizumab 300 mg today, with premedication and the slower rate.
   - Hepatitis B vaccine dose 2 today.
   - Re-baseline MRI of the brain in about three months.
   - Continue occupational therapy; build practice up gradually.
2. **Vitamin D deficiency** (E55.9). Taking cholecalciferol daily. **S**
   - Level in about two and a half months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with lymphocytes | Before each ocrelizumab dose | Completed today | Hemoglobin 13.6 g/dL, white cells 7.9, lymphocytes 1.6, platelets 252 |
| Laboratory | Liver tests and glucose | After high-dose steroids and before each dose | Completed today | ALT 21 U/L, AST 22 U/L; glucose 90 mg/dL |
| Laboratory | Pregnancy test | Before each ocrelizumab dose | Completed today | Urine pregnancy test negative |
| Laboratory | Hepatitis B, HIV and other screening before B-cell therapy | Before the first dose | Up to date | Reviewed at the diagnosis visit: no hepatitis B infection and not immune, so vaccination continues |
| Medication safety | Infusion reactions | With each infusion | Completed today | Mild reaction with dose 1 (throat itch, flushing); premedication and a slower rate today |
| Medication safety | Vaccination | Complete series where possible | Completed today | Hepatitis B dose 2 today; recombinant zoster dose 2 due in two to six months after dose 1 |
| Examination | Hand function: nine-hole peg test, both hands | At diagnosis, after a relapse, and at each review | Completed today | 20.5 seconds right, 23.0 seconds left |
| Referral | Occupational therapy | Through recovery from the relapse | Up to date | Program started a week after the diagnosis visit |
| Imaging | Re-baseline MRI of the brain | Three to six months after starting a disease-modifying therapy | Due | Booked for about three months after the first dose |
| Laboratory | 25-hydroxyvitamin D | About three months after starting replacement | Due | With the re-baseline MRI visit |
| Survey | Mood and anxiety (PHQ-9, GAD-7) | At diagnosis and at each review | Completed today | PHQ-9 5; item 9 scored 0 |
| Self-management | Fatigue: causes and management | Each review | Completed today | Less tired; pacing practice in short blocks with rests |

## Goal progress

- MRI of the brain and spine within one week and a neurology diagnosis within three weeks. Outcome by 2026-03-23: MRI in three days, lumbar puncture in a week, diagnosis and consultation at two weeks. **S**
- High-efficacy disease-modifying therapy started within six weeks of diagnosis, after screening and vaccinations. Outcome by 2026-04-27: Ocrelizumab started three weeks after the diagnosis; PCV20, recombinant zoster and hepatitis B vaccines given first. **S**
- Nine-hole peg times back to within 10 percent of normal in both hands, and full practice resumed. In progress; target 2026-07-13. **S**
- No evidence of disease activity at six months (no relapse, no new or enhancing MRI lesion, no disability progression). In progress; target 2026-10-12. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more. In progress; target 2026-07-13. **S**
- PHQ-9 below 10 throughout. In progress; target 2026-10-12. **S**

## Guideline basis

- Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018), American Academy of Neurology
- Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018), European Committee for Treatment and Research in Multiple Sclerosis / European Academy of Neurology
- Multiple sclerosis in adults: management (NICE guideline NG220) (2022), National Institute for Health and Care Excellence
- Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021), The Lancet Neurology
- Hauser SL, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017;376(3):221-234 (PMID 28002679) (2017), New England Journal of Medicine
- Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019), American Academy of Neurology

## Follow-up

- Re-baseline MRI and review in about ten weeks; occupational therapy continues; call for fever, urinary symptoms or any new neurological symptom. **S**
- Next scheduled visit 2026-07-13: three months on ocrelizumab: re-baseline MRI, B-cell depletion, fatigue, vitamin D and hand function. **S**
